摘要
目的前瞻性研究低强度华法林抗凝合用洛伐他汀对非瓣膜性心房颤动患者脑卒中的预防作用。方法将自愿接受脑卒中预防的628例非瓣膜性心房颤动患者随机分为实验组和对照组各314例。对照组维持目标抗凝强度凝血活酶臣际标准化比率（INR）2．0～3．0；实验组维持目标抗凝强度INR1．5～1．9．并加用洛伐他汀20mg／d，随访7～56个月。结果与对照组比较，实验组出血事件和缺血性卒中的发生率明显降低．5a生存率明显提高。结论低强度华法林抗凝合用洛伐他汀能有效降低非瓣膜性心房颤动患者脑卒中发生率，降低华法林抗凝引起出血的危险性，提高长期生存率。
[Objective] To study prospective effects of low-intensity warfarin plus lovastatin on preventing stroke in patients with non-valvular atrial fibrillation （NVAF）. [Methods] 628 subjects with NVAF were divided at random into warfarin group＇and warfarin plus lovastatin group. The warfarin group was treated with warfarin with international normalized ratio （INR） 2.0-3. 0. The warfarin plus lovastatin group was treated with warfarin plus lovastatin with INR 1. 5-1.9. [Results] Compared with warfarin group, warfarin plus lovastatin group ishowed lower events of bleeding and ischemic stroke, and higher 5-year survival rate. [Conclusion] Low intensity of warfarin anticoagulation plus 10vastatin may decrease the events of bleeding and r stroke, and increase 5-year survival rate in patients with NVAF.
出处
《山东医药》
CAS
北大核心
2007年第1期15-16,共2页
Shandong Medical Journal
关键词
心房颤动
脑血管意外
华法林
洛伐他汀
atrial fibrillation
cerebrovascular accident
warfarin
lovastatin
